MiMedx Group (MDXG) Offers FY18 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to MiMedx Group (MDXG) Offers FY18 Guidance

MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million

December 13, 2017 7:00 AM EST

MARIETTA, Ga., Dec. 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its guidance for full year 2018.

Full Year 2018 Guidance Highlights:The Company's full year 2018 expectations include:

Revenue estimated between $383 to $387 million Gross profit margins expected to be in the range of 89% to 90% Operating Income expected to be in... More